. 2014 Aug 26;32(12):1231–1243. doi: 10.1007/s40273-014-0207-1

Table 1.

Adjuvant chemotherapy recommendation changes with the 12-gene assay

Pre-assay recommendations	Post-assay recommendations, n (%)			Total
Pre-assay recommendations	Observation	Fluoropyrimidine monotherapy^a	FOLFOX^b	Total
Observation	54 (38.3)	8 (5.7)*	6 (4.3)*	68 (48.2)
Fluoropyrimidine monotherapy^a	24 (17.0)**	8 (5.7)	2 (1.4)*	34 (24.1)
FOLFOX^b	21 (14.9)**	2 (1.4)**	16 (11.3)	39 (27.7)
Total	99 (70.2)	18 (12.8)	24 (17.0)	141 (100.0)

Clinical utility data were extracted from Srivastava et al. [15]

5-FU/LV 5-fluorouracil and leucovorin, FOLFOX 5-FU/LV and oxaliplatin

^a5-FU/LV or capecitabine

^bCombination chemotherapy with oxaliplatin

* Increased recommended treatment intensity

** Decreased recommended treatment intensity